Jazz Pharmaceuticals PLC reports results for the quarter ended June 30 - Earnings Summary

Jazz Pharmaceuticals

05/08/2025 23:20

Jazz Pharmaceuticals PLC JAZZ.OQ reported a quarterly adjusted loss of $8.25​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $5.30.  The mean expectation of eighteen analysts for the quarter was for a loss of $7.60 per share. Wall Street expected results to range from $-9.37 to $-4.34 per share.

Revenue rose 2.1% to $1.05 billion from a year ago; analysts expected $1.05 billion.

Jazz Pharmaceuticals PLC's reported EPS for the quarter was a loss of $11.74​.

The company reported a quarterly loss of $718.47 million.

Jazz Pharmaceuticals PLC shares had risen by 9.4% this quarter and lost 5.7% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 1,368.1% in the last three months.​

In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC is $178.21, about 36.5% above its last closing price of $113.20

This summary was machine generated from LSEG data August 5 at 10:19 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-7.60
-8.25
Missed
Mar. 31 2025
4.66
1.68
Missed
Dec. 31 2024
5.81
6.60
Beat
Sep. 30 2024
5.50
6.61
Beat